Newman Dignan & Sheerar Inc’s Adaptimmune Therapeutics ADAP Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,957	Closed	-$6.7K	–	181
2025 Q2	$6.7K	Hold	27,957	–	–	﹤0.01%	194
2025 Q1	$5.51K	Hold	27,957	–	–	﹤0.01%	175
2024 Q4	$15.1K	Hold	27,957	–	–	﹤0.01%	181
2024 Q3	$20.6K	Buy	+27,957	New	+$31.7K	﹤0.01%	185
2024 Q1	–	Sell	-23,031	Closed	-$18.3K	–	172
2023 Q4	$18.3K	Buy	+23,031	New	+$13K	0.01%	177
2023 Q3	–	Sell	-19,364	Closed	-$17.9K	–	166
2023 Q2	$17.9K	Buy	+19,364	New	+$23.1K	0.01%	185

Other funds holding ADAP

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Newman Dignan & Sheerar Inc's ADAP Position: Q3 2025 in Review

Newman Dignan & Sheerar Inc sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 27,957 shares — an estimated $6.7K sold.

Newman Dignan & Sheerar Inc first reported a position in ADAP in Q2 2023 and held it in 6 quarters. The position peaked at $20.6K in Q3 2024. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

Newman Dignan & Sheerar Inc reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
Newman Dignan & Sheerar Inc sold 27,957 Adaptimmune Therapeutics shares in Q3 2025, an estimated $6.7K.
Newman Dignan & Sheerar Inc first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 6 quarters.
Newman Dignan & Sheerar Inc's Adaptimmune Therapeutics position peaked at $20.6K in Q3 2024.
55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q3 2025, filed 9 Oct 2025.